Open an account

Blueprint Medicines

BPMC · NASDAQ

Price unavailable right now.

No price history for this range.

About BPMC

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 682 full-time employees. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.

Employees
649
Headquarters
Cambridge, Massachusetts
Listed
Apr 30, 2015
Sector
Health Care
Industry
Biotechnology
Website
blueprintmedicines.com

BPMC key statistics

This section is temporarily unavailable. Refresh to try again.

BPMC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 18.0% on average.

  1. Q2 FY23: reported -$2.19 per share against an estimate of -$2.59
  2. Q3 FY23: reported -$2.20 per share against an estimate of -$2.41
  3. Q4 FY23: reported -$1.82 per share against an estimate of -$2.08
  4. Q1 FY24: reported -$1.32 per share against an estimate of -$1.70
  5. Q2 FY24: reported -$0.80 per share against an estimate of -$1.32
  6. Q3 FY24: reported -$0.89 per share against an estimate of -$0.9859
  7. Q4 FY24: reported -$0.79 per share against an estimate of -$0.7179
  8. Q1 FY25: reported -$0.74 per share against an estimate of -$0.536

BPMC news

  • Press releaseBusiness Wire

    Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction

  • Press releaseBusiness Wire

    Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

  • Vandana Singh

    Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD

  • Vandana Singh

    Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders

  • Press releaseBusiness Wire

    BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

  • Press releasePRNewswire

    Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

Similar companies

Companies in the same industry as Blueprint Medicines

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.